CA2354495A1 - Method for the determination of local no supply in the vascular system of a mammal - Google Patents
Method for the determination of local no supply in the vascular system of a mammal Download PDFInfo
- Publication number
- CA2354495A1 CA2354495A1 CA002354495A CA2354495A CA2354495A1 CA 2354495 A1 CA2354495 A1 CA 2354495A1 CA 002354495 A CA002354495 A CA 002354495A CA 2354495 A CA2354495 A CA 2354495A CA 2354495 A1 CA2354495 A1 CA 2354495A1
- Authority
- CA
- Canada
- Prior art keywords
- nitrite
- local
- endothelial
- vascular
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 26
- 230000002792 vascular Effects 0.000 title claims abstract description 20
- 241000124008 Mammalia Species 0.000 title claims abstract description 11
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 claims abstract description 29
- 210000004369 blood Anatomy 0.000 claims abstract description 19
- 239000008280 blood Substances 0.000 claims abstract description 19
- 229910002651 NO3 Inorganic materials 0.000 claims abstract description 8
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000012089 stop solution Substances 0.000 claims abstract description 7
- 238000006243 chemical reaction Methods 0.000 claims abstract description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- 206010048554 Endothelial dysfunction Diseases 0.000 claims description 11
- 230000008694 endothelial dysfunction Effects 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-DYCDLGHISA-N deuterium hydrogen oxide Chemical compound [2H]O XLYOFNOQVPJJNP-DYCDLGHISA-N 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract description 172
- 239000000243 solution Substances 0.000 description 26
- 241000282414 Homo sapiens Species 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 210000000245 forearm Anatomy 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- 206010020772 Hypertension Diseases 0.000 description 10
- 230000003511 endothelial effect Effects 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 230000004060 metabolic process Effects 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 230000004087 circulation Effects 0.000 description 8
- 239000007789 gas Substances 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 208000037849 arterial hypertension Diseases 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 6
- 206010003210 Arteriosclerosis Diseases 0.000 description 5
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 5
- 229960004373 acetylcholine Drugs 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 210000001772 blood platelet Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 230000001631 hypertensive effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 208000037803 restenosis Diseases 0.000 description 4
- 235000011121 sodium hydroxide Nutrition 0.000 description 4
- 230000024883 vasodilation Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000008753 endothelial function Effects 0.000 description 3
- 210000003038 endothelium Anatomy 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229940079877 pyrogallol Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000005541 ACE inhibitor Substances 0.000 description 2
- 101800004538 Bradykinin Proteins 0.000 description 2
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 2
- 102100035792 Kininogen-1 Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229940082615 organic nitrates used in cardiac disease Drugs 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000006442 vascular tone Effects 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 108010061951 Methemoglobin Proteins 0.000 description 1
- NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 description 1
- NTNWOCRCBQPEKQ-UHFFFAOYSA-N NG-mono-methyl-L-arginine Natural products CN=C(N)NCCCC(N)C(O)=O NTNWOCRCBQPEKQ-UHFFFAOYSA-N 0.000 description 1
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 1
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 1
- ODUCDPQEXGNKDN-UHFFFAOYSA-N Nitrogen oxide(NO) Natural products O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 description 1
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 240000007313 Tilia cordata Species 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- HGAZMNJKRQFZKS-UHFFFAOYSA-N chloroethene;ethenyl acetate Chemical compound ClC=C.CC(=O)OC=C HGAZMNJKRQFZKS-UHFFFAOYSA-N 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000000835 electrochemical detection Methods 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 239000000066 endothelium dependent relaxing factor Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000013147 laser angioplasty Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000036513 peripheral conductance Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Disclosed in a method for the determination of local nitric oxide supply in the vascular system of a mammal, comprising the steps of preventing rapid conversion of nitrite to nitrate in a blood sample by addition of a stop solution to the blood sample, and then recovering and measuring the nitrite.
Description
METHOD FOR THE DETERMINATION OF LOCAL NO SUPPLY IN THE
VASCULAR SYSTEM OF A MAMMAL
The present application is a division of application n°
VASCULAR SYSTEM OF A MAMMAL
The present application is a division of application n°
2,244,454 filed on July 27, 1998.
Description The original description of the parent application n°
2,244,454 discloses a pharmaceutical composition of a steril, injectable physiologically acceptable solution containing nitric oxide (NO), a method for its preparation and a detection method for physiologically present NO.
Physiologically present nitric oxide (NO), through a variety of biological functions, can influence essential key processes in the development of arteriosclerosis, such as relaxation of smooth vascular muscles, inhibition of adhesion of thrombocytes, granulocytes and monocytes to the vascular wall, inhibition of proliferation of secretory smooth muscle cells and direct effects on endothelial metabolism.
Thus, in recent years it has been shown that endothelial nitric oxide (NO) influences the metabolism as well as the function of the vascular wall by a great many mechanisms:
1. by stimulation of soluble guanylate cyclase it leads to the relaxation of smooth vascular muscles, and 2. thus participates in the regulation of peripheral vascular resistance and arterial blood pressure, 3. in addition, it inhibits mitogenesis and proliferation of smooth vascular muscle cells, 4. it suppresses adhesion of thrombocytes, monocytes and neutrophil granulocytes to the vascular wall, and 5. it directly influences the metabolism of endothelial cells, e.g., by altered expression of adhesive molecules on the superficial membrane. Overviews of this?? are found in:
1. Moncada, S. and Higgs, A. The L-arginine-nitric oxide pathway. N.EngI.J.Med. 329:
2002-2012, 1993.
2. Radoniski, M.W. and Moncada, S. Regulation of vascular homeostasis by nitric oxide.
Thromb. Haemost. 70:36-41, 1993.
3. Snyder, S.H. and Bredt, D.S. Biological roles of nitric oxide. Sci AM 266 (5):68-77, 1992 .
4. Gibbons, G.H. and Dzau, V.J. The emerging concept of vascular remodeling. N. Engl. J.
Med. 330:1431-1438, 1994.
All of the processes mentioned represent key events in the development of pathologic vascular wall changes in arteriosclerosis. Recognized risk factors of arterio-sclerosis, which also affect endothelial function, are arterial hyper-tension, hyperlipoproteinemia, diabetes mellitus, nicotine consumption and possibly age and sex (see Moncada, S. and Higgs, A. The L-arginine-nitric oxide pathway. N. Engl. J. Med. 329:2002-2012, 1993; Ross, R. The pathogenesis of arteriosclerosis - an update. N. Engl. J.
Med. 324 (No. 8):488-500, 1986; Safar, M.E. and Frohlich, E.D. The arterial system in hypertension. A prospective view. Hypertension 26:10-14, 1995).
However, the pathophysioloqically significant demonstration of altered activity of endothelial NO synthesis has hitherto been successful only in experimental preparations with cultured cells or isolated organ circulatory systems in which a quantification of NO or its catabolic products was possible. Regarding this, however, in man so far only phenomenological findings with regard to an altered acetylcholine-induced flow response in various vascular regions have been described as indirect markers of endothelium-dependent vasodilatation. Exact quantification of the activity of endothelial constitutive NO synthesis in man as an indicator of endothelial dysfunction has previously not been possible.
Lastly, in past decades a variety of classes of NO donors for the treatment of arteriosclerotic vascular wall alterations such as, for example, coronary heart disease, have been successfully developed and employed (overviews on this are found in Feelisch, M. The biochemical pathways of nitric oxide formation from nitrovasodilators: appropriate choice of exogenous NO donors and aspects of preparation and handling of aqueous NO solutions. J. Cardiovasc.
Pharmacol. 17 (suppl. 3):525-533, 1991; Feelisch, M. and Noack, E. The vitro metabolism of nitrovasodilators and their conversion into vasoactive species. In: Heart Failure Mechanisms and Management, edited by Lewis, B.S. and Kimchi, A., Springer: Berlin, Heidelberg, 1991, p. 241-255;
Harrison, D.G. and Bates, J.N. The nitrovasodilators.
Circulation 87:1461-1467, 1993; De Caterina, R. Nitrate als Thrombozytenfunctionshemmer [Nitrates as thrombocyte function inhibitors). Z. Kardiol. 83:463-473, 1994).
NO donors act in the arterial as well as in the venous portion of the circulatory system and also influence NO-dependently the interaction of the vascular wall with the corpuscular components of the blood (thrombocytes, neutrophil granulocytes and monocytes). To date, however, there has as yet been no therapeutic development that permits NO to be used directly in the form of authentic NO
solutions in the human circulatory system. This may have its roots in the extremely rapid metabolism and inactivation of NO in the human circulatory system which, on the one hand, impedes successful and targeted introduction of NO into the human circulatory system but, on the other, offers the advantage of potentially being able to obtain very high NO doses locally without having to put up with accompanying systemic side effects. With regard to the abovementioned extensive antiarteriosclerotic properties of NO, the last point in particular seems extremely significant for all intravascular interventions in peripheral and coronary arteries.
Over 370,000 coronary interventions (PTCA, etc.) annually are now performed in highly developed industrial nations such as the USA and Germany (see Gleichmann, U., Mannebach, H., and Lichtlen, P. 10. Bericht uber Struktur and Leistungszahlen der Herzkatheterlabors in der Bundesrepublik Deutschland [Report on structure and performance of the cardiac catheter laboratory in the Federal Republic. of Germany]. Z. Kardiol. 84:327-333, 1995) .
The initial rate of success runs to 90%, but 10% of PTCAs lead to early occlusion or thrombus formation. In addition, in 25 - 50% of cases, depending upon the reference cited, restenosis develops in the first six months after surgery.
The total number of all angioplasties performed worldwide is estimated at over one million by the year 2000, which in turn means that up to 400,000 restenoses annually are to be expected. These figures underscore the urgent need for treatment to reduce the rate of acute and long-term restenosis after PTCA. Systemic pharmacologic studies of intervention with calcium antagonists, organic nitrates and ACE inhibitors have so far shown no effect on the rate of restenosis. Even the development of a variety of alternative mechanical methods (directional atherectomy, laser angioplasty, stent implantation, rotablation) has failed to result in an overall reduction of the rate of restenosis, these methods remaining limited to certain niche indications. This has recently led to the development of new LDD (local drug delivery) systems, such as coated stmt prostheses, the Kaplan-Simpson infusion catheter (Stanford University), the microinfusion catheter (Cordis) or the porous PTCA balloon catheter (ACS). With these systems it seems possible for the first time to introduce high local doses of a medicinal drug into the vascular wall of the coronary arteries. Because of NO's rapid metabolism in human blood, it now seems extremely desirable and useful to introduce NO into the coronary vessel locally in high doses during coronary interventions and thus to utilize all the biological effects of NO mentioned by way of introduction, such as relaxation of smooth vascular muscles, inhibition of adhesion of thrombocytes and neutrophil monocytes, at a local spot without accompanying systemic effects, such as, for example, a critical pressure drop, developing because of high doses.
As already mentioned at the beginning, arterial hyper-tension, hyperlipoproteinemia and diabetes mellitus are the essential atherogenic risk factors. Epidemiologic data indicate a total mortality rate of 25% for arterial hypertension and its secondary cardiovascular diseases alone; (see Strauer, B.E. Das Hochdruckherz [The hypertensive heart), Berlin, Heidelberg, New York: Springer Verlag, 1991, pp. 1-241).
Endothelial dysfunction, which may be defined as the essential pacemaker of arteriosclerosis, has to date not been detectable by any routine clinical parameter.
Consequently, from the general point of view of an early diagnosis, as well as a differential therapeutic influence on such endothelial dysfunction, a reliable detection method for the field of cardiovascular medicine is desirable.
The invention as broadly disclosed is addressed, therefore, to the problem of making available a pharmaceutical composition of a sterile, injectable, physiologically acceptable solution with a content of NO, a method for its production, as well as a method of detection for physilogically present NO.
Description The original description of the parent application n°
2,244,454 discloses a pharmaceutical composition of a steril, injectable physiologically acceptable solution containing nitric oxide (NO), a method for its preparation and a detection method for physiologically present NO.
Physiologically present nitric oxide (NO), through a variety of biological functions, can influence essential key processes in the development of arteriosclerosis, such as relaxation of smooth vascular muscles, inhibition of adhesion of thrombocytes, granulocytes and monocytes to the vascular wall, inhibition of proliferation of secretory smooth muscle cells and direct effects on endothelial metabolism.
Thus, in recent years it has been shown that endothelial nitric oxide (NO) influences the metabolism as well as the function of the vascular wall by a great many mechanisms:
1. by stimulation of soluble guanylate cyclase it leads to the relaxation of smooth vascular muscles, and 2. thus participates in the regulation of peripheral vascular resistance and arterial blood pressure, 3. in addition, it inhibits mitogenesis and proliferation of smooth vascular muscle cells, 4. it suppresses adhesion of thrombocytes, monocytes and neutrophil granulocytes to the vascular wall, and 5. it directly influences the metabolism of endothelial cells, e.g., by altered expression of adhesive molecules on the superficial membrane. Overviews of this?? are found in:
1. Moncada, S. and Higgs, A. The L-arginine-nitric oxide pathway. N.EngI.J.Med. 329:
2002-2012, 1993.
2. Radoniski, M.W. and Moncada, S. Regulation of vascular homeostasis by nitric oxide.
Thromb. Haemost. 70:36-41, 1993.
3. Snyder, S.H. and Bredt, D.S. Biological roles of nitric oxide. Sci AM 266 (5):68-77, 1992 .
4. Gibbons, G.H. and Dzau, V.J. The emerging concept of vascular remodeling. N. Engl. J.
Med. 330:1431-1438, 1994.
All of the processes mentioned represent key events in the development of pathologic vascular wall changes in arteriosclerosis. Recognized risk factors of arterio-sclerosis, which also affect endothelial function, are arterial hyper-tension, hyperlipoproteinemia, diabetes mellitus, nicotine consumption and possibly age and sex (see Moncada, S. and Higgs, A. The L-arginine-nitric oxide pathway. N. Engl. J. Med. 329:2002-2012, 1993; Ross, R. The pathogenesis of arteriosclerosis - an update. N. Engl. J.
Med. 324 (No. 8):488-500, 1986; Safar, M.E. and Frohlich, E.D. The arterial system in hypertension. A prospective view. Hypertension 26:10-14, 1995).
However, the pathophysioloqically significant demonstration of altered activity of endothelial NO synthesis has hitherto been successful only in experimental preparations with cultured cells or isolated organ circulatory systems in which a quantification of NO or its catabolic products was possible. Regarding this, however, in man so far only phenomenological findings with regard to an altered acetylcholine-induced flow response in various vascular regions have been described as indirect markers of endothelium-dependent vasodilatation. Exact quantification of the activity of endothelial constitutive NO synthesis in man as an indicator of endothelial dysfunction has previously not been possible.
Lastly, in past decades a variety of classes of NO donors for the treatment of arteriosclerotic vascular wall alterations such as, for example, coronary heart disease, have been successfully developed and employed (overviews on this are found in Feelisch, M. The biochemical pathways of nitric oxide formation from nitrovasodilators: appropriate choice of exogenous NO donors and aspects of preparation and handling of aqueous NO solutions. J. Cardiovasc.
Pharmacol. 17 (suppl. 3):525-533, 1991; Feelisch, M. and Noack, E. The vitro metabolism of nitrovasodilators and their conversion into vasoactive species. In: Heart Failure Mechanisms and Management, edited by Lewis, B.S. and Kimchi, A., Springer: Berlin, Heidelberg, 1991, p. 241-255;
Harrison, D.G. and Bates, J.N. The nitrovasodilators.
Circulation 87:1461-1467, 1993; De Caterina, R. Nitrate als Thrombozytenfunctionshemmer [Nitrates as thrombocyte function inhibitors). Z. Kardiol. 83:463-473, 1994).
NO donors act in the arterial as well as in the venous portion of the circulatory system and also influence NO-dependently the interaction of the vascular wall with the corpuscular components of the blood (thrombocytes, neutrophil granulocytes and monocytes). To date, however, there has as yet been no therapeutic development that permits NO to be used directly in the form of authentic NO
solutions in the human circulatory system. This may have its roots in the extremely rapid metabolism and inactivation of NO in the human circulatory system which, on the one hand, impedes successful and targeted introduction of NO into the human circulatory system but, on the other, offers the advantage of potentially being able to obtain very high NO doses locally without having to put up with accompanying systemic side effects. With regard to the abovementioned extensive antiarteriosclerotic properties of NO, the last point in particular seems extremely significant for all intravascular interventions in peripheral and coronary arteries.
Over 370,000 coronary interventions (PTCA, etc.) annually are now performed in highly developed industrial nations such as the USA and Germany (see Gleichmann, U., Mannebach, H., and Lichtlen, P. 10. Bericht uber Struktur and Leistungszahlen der Herzkatheterlabors in der Bundesrepublik Deutschland [Report on structure and performance of the cardiac catheter laboratory in the Federal Republic. of Germany]. Z. Kardiol. 84:327-333, 1995) .
The initial rate of success runs to 90%, but 10% of PTCAs lead to early occlusion or thrombus formation. In addition, in 25 - 50% of cases, depending upon the reference cited, restenosis develops in the first six months after surgery.
The total number of all angioplasties performed worldwide is estimated at over one million by the year 2000, which in turn means that up to 400,000 restenoses annually are to be expected. These figures underscore the urgent need for treatment to reduce the rate of acute and long-term restenosis after PTCA. Systemic pharmacologic studies of intervention with calcium antagonists, organic nitrates and ACE inhibitors have so far shown no effect on the rate of restenosis. Even the development of a variety of alternative mechanical methods (directional atherectomy, laser angioplasty, stent implantation, rotablation) has failed to result in an overall reduction of the rate of restenosis, these methods remaining limited to certain niche indications. This has recently led to the development of new LDD (local drug delivery) systems, such as coated stmt prostheses, the Kaplan-Simpson infusion catheter (Stanford University), the microinfusion catheter (Cordis) or the porous PTCA balloon catheter (ACS). With these systems it seems possible for the first time to introduce high local doses of a medicinal drug into the vascular wall of the coronary arteries. Because of NO's rapid metabolism in human blood, it now seems extremely desirable and useful to introduce NO into the coronary vessel locally in high doses during coronary interventions and thus to utilize all the biological effects of NO mentioned by way of introduction, such as relaxation of smooth vascular muscles, inhibition of adhesion of thrombocytes and neutrophil monocytes, at a local spot without accompanying systemic effects, such as, for example, a critical pressure drop, developing because of high doses.
As already mentioned at the beginning, arterial hyper-tension, hyperlipoproteinemia and diabetes mellitus are the essential atherogenic risk factors. Epidemiologic data indicate a total mortality rate of 25% for arterial hypertension and its secondary cardiovascular diseases alone; (see Strauer, B.E. Das Hochdruckherz [The hypertensive heart), Berlin, Heidelberg, New York: Springer Verlag, 1991, pp. 1-241).
Endothelial dysfunction, which may be defined as the essential pacemaker of arteriosclerosis, has to date not been detectable by any routine clinical parameter.
Consequently, from the general point of view of an early diagnosis, as well as a differential therapeutic influence on such endothelial dysfunction, a reliable detection method for the field of cardiovascular medicine is desirable.
The invention as broadly disclosed is addressed, therefore, to the problem of making available a pharmaceutical composition of a sterile, injectable, physiologically acceptable solution with a content of NO, a method for its production, as well as a method of detection for physilogically present NO.
The invention as claimed hereinafter is however restricted to the latter method. More specifically, it is directed to a method for the determination of local NO supply in the vascular system of a mammal, comprising the steps of preventing rapid conversion of nitrite to nitrate in a blood sample by addition of a stop solution to said blood sample, and then recovering and measuring the nitrite.
The above mentioned pharmaceutical composition preferably consists of 0.9% of a physiological sodium chloride solution saturated with NO.
In the pharmaceutical composition of the invention, the saturation concentration of the NO in the 0.9% sodium chloride solution decreases differentially with increasing temperature.
The value of the saturation concentration of NO in the 0.9%
sodium chloride solution at 0°C is 3.26 NO (umol/1), at 25°C
1.85 NO (umol/1), at 37°C 1.52 NO (umol/1) and at 50°C 1.26 NO (umol/1) .
The pharmaceutical composition is prepared according to the invention by passing argon with the exclusion of oxygen, through a sterile, injectable 0.9% sodium chloride solution until all residual oxygen content is removed and then passing NO through the 0.9% sodium chloride solution up to the saturation concentration of the NO in the latter.
The NO solution according to the invention can, according to a another embodiment of the invention, be used for preparing a pharmaceutical composition for treating endothelial dysfunction in mammals.
The following Example 1 explains the construction of the apparatus for the preparation of a sterile, injectable NO
solution and its production.
Example 1 a) Configuration of apparatus The configuration of the apparatus is shown in Drawing 1, wherein:
1 denotes a NO 3.0 reservoir (AGA);
2, an argon 5.0 reservoir (Linde);
3, a gas washing bottle with 5%
pyrogallol (pyrogallol z.A. 612, Merck) in saturated KOH (w: v);
4, a gas washing bottle with KOH z.A.
5033 (Merck), 20%;
5, a gas washing bottle, dry;
6, a round bottom three-necked flask (250 ml), charged with 0.9% NaCl solution with 3 ground inserts, in each of which there are incorporated:
a) a stopcock b) a Luer-lock three-way stopcock c) a three-way stopcock 7, a gas washing bottle, empty, as water trap 8, a gas washing bottle with KOH z.A.
5033 (Merck), as water trap;
A denotes the respective gas-tight ground joints;
B a gas-tight three-way stopcock;
C denotes gas-tight ground joints;
D a gas-tight three-way cock;
E gas-tight ground joints for connection of the respective gas washing bottles.
All parts of the apparatus are connected by gas-tight hoses (type Tygon R 3603*). Teflon Plastibrand* (Brand) seals are used as seals and, as filters, Millex type GS* filters, 0.2 ~,m (millipore) .
b) Preparation of a sterile NO solution All glassware is cleaned by means of concentrated caustic soda solution (NaOH) and in every case rewashed 10 times with aqua bidestillata and HPLC
water. Then the successively connected gas washing bottles (3) , (4) , (5) , of which in (3) pyrogallol (5%) in saturated KOH (w:v) is placed for the removal of traces of oxygen, in (4) 20% KOH is placed for the removal of higher nitrogen oxides and (5) is dry, and the three-necked round bottom flask connected therewith, in which NaCl solution (0.9%) is placed, are gassed for 45 min with argon.
The portion of the NaCl solution found in the riser tube is discarded. The oxygen is removed from a sterile, gas-tight syringe and the associated * trademarks conducting systems as well as filters by a sterile 0.2 ~.m filter by means of argon and the volume of NaCl necessary for dilution of the NO solution is discharged into the oxygen-free, gas-tight syringe.
Lastly, the system is gassed for 45 min with nitrogen oxide (NO) .
Oxygen is completely removed anew with argon from the filters and conducting systems that lead to the 10 syringe with dilution solution present. The portion of NO solution found within the riser tube is discarded and after that the entire conducting system and the sterile filter are thoroughly washed with NO solution.
The necessary volume of NO solution is immediately transferred into the gas-tight primary packing previously prepared with given NaC solution via the three-way stopcock (B) through sterile filters, which may in each instance be an ampoule, vial, syringe, etc.
As aforesaid, the invention as claimed hereinafter is directed to a detection method for the quantitative determination of endothelial dysfunction in mammals.
Previously, endothelial dysfunction in patients with arterial hypertension, diabetes mellitus and/or hyperlipoproteinemia could only be established by costly diagnostic measures such as arterial puncture with subsequent local administration of acetylcholine and hemodynamic quantification of the resultant flow response in the circulatory region examined in comparison to a standard age-appropriate group (see Calver, A., Collier, J., and Vallance, P. Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J. Clin. Invest.
90:2548-2554, 1992; Creager, M.A., Cooke, J.P., Mendelsohn, M.E., Gallagher, S.J., Coleman, S.M., Loscalzo, J., and Dzau, V.j. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J. Clin. Invest.
86:228-234, 1990; Kelm, M., Preik, M., Motz, W., and Strauer, B.E. Endotheliale Funktion bei Patienten mit arterieller Hypertonie (Endothelial function in patients with arterial hypertension]. In: Zellulare Mechanismen den Herz-Kreislaufregulation [Cellular mechanisms of cardio-vascular regulation), edited by Gante, D., Stuttgart:
Schattauer, 1993, p. 139-150; Linden, L., Kiowski, W., Bizhler, F . R . , and Lizscher, T . F . Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Circulation 81:1762-1767, 1990; Panza, J.A.1 Epstein, S.E., and Quyyumi, A.A.
Circadian variation in vascular tone and its relation to a a-sympathetic vasoconstrictor activity. N. Engl. J. Med.
325:986-990, 1991).
In addition, in longitudinal studies on this purely phenomenological approach it was sought to document a possible therapeutic effect on endothelial dysfunction in, for example, patients with arterial hypertension by hypotensive therapy with ACE inhibitors, which however, was unsuccessful because of the great variation in the methods of the investigational approach; (see Creager, M.A. and Roddy, M.-A. Effect of captopril and enalapril on endothelial function in hypertensive patients. Hypertension 24:499-505, 1994).
The above mentioned pharmaceutical composition preferably consists of 0.9% of a physiological sodium chloride solution saturated with NO.
In the pharmaceutical composition of the invention, the saturation concentration of the NO in the 0.9% sodium chloride solution decreases differentially with increasing temperature.
The value of the saturation concentration of NO in the 0.9%
sodium chloride solution at 0°C is 3.26 NO (umol/1), at 25°C
1.85 NO (umol/1), at 37°C 1.52 NO (umol/1) and at 50°C 1.26 NO (umol/1) .
The pharmaceutical composition is prepared according to the invention by passing argon with the exclusion of oxygen, through a sterile, injectable 0.9% sodium chloride solution until all residual oxygen content is removed and then passing NO through the 0.9% sodium chloride solution up to the saturation concentration of the NO in the latter.
The NO solution according to the invention can, according to a another embodiment of the invention, be used for preparing a pharmaceutical composition for treating endothelial dysfunction in mammals.
The following Example 1 explains the construction of the apparatus for the preparation of a sterile, injectable NO
solution and its production.
Example 1 a) Configuration of apparatus The configuration of the apparatus is shown in Drawing 1, wherein:
1 denotes a NO 3.0 reservoir (AGA);
2, an argon 5.0 reservoir (Linde);
3, a gas washing bottle with 5%
pyrogallol (pyrogallol z.A. 612, Merck) in saturated KOH (w: v);
4, a gas washing bottle with KOH z.A.
5033 (Merck), 20%;
5, a gas washing bottle, dry;
6, a round bottom three-necked flask (250 ml), charged with 0.9% NaCl solution with 3 ground inserts, in each of which there are incorporated:
a) a stopcock b) a Luer-lock three-way stopcock c) a three-way stopcock 7, a gas washing bottle, empty, as water trap 8, a gas washing bottle with KOH z.A.
5033 (Merck), as water trap;
A denotes the respective gas-tight ground joints;
B a gas-tight three-way stopcock;
C denotes gas-tight ground joints;
D a gas-tight three-way cock;
E gas-tight ground joints for connection of the respective gas washing bottles.
All parts of the apparatus are connected by gas-tight hoses (type Tygon R 3603*). Teflon Plastibrand* (Brand) seals are used as seals and, as filters, Millex type GS* filters, 0.2 ~,m (millipore) .
b) Preparation of a sterile NO solution All glassware is cleaned by means of concentrated caustic soda solution (NaOH) and in every case rewashed 10 times with aqua bidestillata and HPLC
water. Then the successively connected gas washing bottles (3) , (4) , (5) , of which in (3) pyrogallol (5%) in saturated KOH (w:v) is placed for the removal of traces of oxygen, in (4) 20% KOH is placed for the removal of higher nitrogen oxides and (5) is dry, and the three-necked round bottom flask connected therewith, in which NaCl solution (0.9%) is placed, are gassed for 45 min with argon.
The portion of the NaCl solution found in the riser tube is discarded. The oxygen is removed from a sterile, gas-tight syringe and the associated * trademarks conducting systems as well as filters by a sterile 0.2 ~.m filter by means of argon and the volume of NaCl necessary for dilution of the NO solution is discharged into the oxygen-free, gas-tight syringe.
Lastly, the system is gassed for 45 min with nitrogen oxide (NO) .
Oxygen is completely removed anew with argon from the filters and conducting systems that lead to the 10 syringe with dilution solution present. The portion of NO solution found within the riser tube is discarded and after that the entire conducting system and the sterile filter are thoroughly washed with NO solution.
The necessary volume of NO solution is immediately transferred into the gas-tight primary packing previously prepared with given NaC solution via the three-way stopcock (B) through sterile filters, which may in each instance be an ampoule, vial, syringe, etc.
As aforesaid, the invention as claimed hereinafter is directed to a detection method for the quantitative determination of endothelial dysfunction in mammals.
Previously, endothelial dysfunction in patients with arterial hypertension, diabetes mellitus and/or hyperlipoproteinemia could only be established by costly diagnostic measures such as arterial puncture with subsequent local administration of acetylcholine and hemodynamic quantification of the resultant flow response in the circulatory region examined in comparison to a standard age-appropriate group (see Calver, A., Collier, J., and Vallance, P. Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J. Clin. Invest.
90:2548-2554, 1992; Creager, M.A., Cooke, J.P., Mendelsohn, M.E., Gallagher, S.J., Coleman, S.M., Loscalzo, J., and Dzau, V.j. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J. Clin. Invest.
86:228-234, 1990; Kelm, M., Preik, M., Motz, W., and Strauer, B.E. Endotheliale Funktion bei Patienten mit arterieller Hypertonie (Endothelial function in patients with arterial hypertension]. In: Zellulare Mechanismen den Herz-Kreislaufregulation [Cellular mechanisms of cardio-vascular regulation), edited by Gante, D., Stuttgart:
Schattauer, 1993, p. 139-150; Linden, L., Kiowski, W., Bizhler, F . R . , and Lizscher, T . F . Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Circulation 81:1762-1767, 1990; Panza, J.A.1 Epstein, S.E., and Quyyumi, A.A.
Circadian variation in vascular tone and its relation to a a-sympathetic vasoconstrictor activity. N. Engl. J. Med.
325:986-990, 1991).
In addition, in longitudinal studies on this purely phenomenological approach it was sought to document a possible therapeutic effect on endothelial dysfunction in, for example, patients with arterial hypertension by hypotensive therapy with ACE inhibitors, which however, was unsuccessful because of the great variation in the methods of the investigational approach; (see Creager, M.A. and Roddy, M.-A. Effect of captopril and enalapril on endothelial function in hypertensive patients. Hypertension 24:499-505, 1994).
Moreover, the extent to which arteriosclerotically induced endothelial dysfunction is based on reduced NO synthesis and/or increased NO catabolism cannot be differentiated by the purely phenomenological approach of an altered acetylcholine-dependent flow response; (see Kelm, M., Preik, M., Kbster, A., Heinzelmann, A., Motz, W., and Strauer, B.E. Reduced nitric oxide dependent vasodilation following application of organic nitrates in essential hypertension. In: The biology of nitric oxide, edited by Moncada, S., London: Portland Press Ltd., 1994, p. 509-513;
Kelm, M., Feelisch M., Krebber, T., Deussen, A., Motz, W., and Strauer, B.E. The role of nitric oxide (NO) in the regulation of coronary vascular tone in hearts from hypertensive rats; maintenance of NO forming capacity and increased basal production of NO. Hypertension 25:186-193, 1995; Kelm, M., Preik, M., Hafner, D., Strauer, B.E.
Evidence for a multifactorial process involved in the impaired flow responses to nitric oxide in hypertensive patients with endothelial dysfunction. Hypertension, in press, 1996) .
The detection method according to the invention permits the measurement of the nitrite content in the whole blood of mammals, particularly in human whole blood, nitrite being the specific marker for the activity of endothelial constitutive NO synthesis in the human circulatory system.
The following example, Example 2, explains the detection method.
Kelm, M., Feelisch M., Krebber, T., Deussen, A., Motz, W., and Strauer, B.E. The role of nitric oxide (NO) in the regulation of coronary vascular tone in hearts from hypertensive rats; maintenance of NO forming capacity and increased basal production of NO. Hypertension 25:186-193, 1995; Kelm, M., Preik, M., Hafner, D., Strauer, B.E.
Evidence for a multifactorial process involved in the impaired flow responses to nitric oxide in hypertensive patients with endothelial dysfunction. Hypertension, in press, 1996) .
The detection method according to the invention permits the measurement of the nitrite content in the whole blood of mammals, particularly in human whole blood, nitrite being the specific marker for the activity of endothelial constitutive NO synthesis in the human circulatory system.
The following example, Example 2, explains the detection method.
Example 2 Method for the determination of nitrite in human whole blood 1 ml blood is placed in a syringe containing 1 ml stop solution of 1 mol/L concentrated NaOH and immediately thereafter 50 ~.1 of a 1 mol/L concentrated phosphoric acid (H3P04) is added for neutralization of the blood/NaOH
mixture obtained. Said mixture is centrifuged in a centrifuge (Universal 30RF, Hettich firm) for 5 min at 10,0000 g. The supernatant obtained is decanted in ultrafiltration tubes (Sartorius cut-off 10,000). It is centrifuged anew for 15 min at 2,000 g (Eppendorf centrifuge 5402 C, Eppendorf firm). The water-white ultrafiltrate obtained is transferred to reaction vessels holding 1.5 ml volumes and diluted with HPLC water in the ratio of 1:10.
This is either followed immediately by the analysis or the samples obtained are stored at -80°C for a period of one month.
Pharmacoloaic studies 1. Nitrite as st~ecific diagnostic anent of cNOS
Our own knowledge of the metabolism of NO in the human cardiovascular system was taken as the basis and, building on that, nitrite, as a specific marker of the activity of endothelial constitutive NO synthesis, was accurately and precisely measured.
mixture obtained. Said mixture is centrifuged in a centrifuge (Universal 30RF, Hettich firm) for 5 min at 10,0000 g. The supernatant obtained is decanted in ultrafiltration tubes (Sartorius cut-off 10,000). It is centrifuged anew for 15 min at 2,000 g (Eppendorf centrifuge 5402 C, Eppendorf firm). The water-white ultrafiltrate obtained is transferred to reaction vessels holding 1.5 ml volumes and diluted with HPLC water in the ratio of 1:10.
This is either followed immediately by the analysis or the samples obtained are stored at -80°C for a period of one month.
Pharmacoloaic studies 1. Nitrite as st~ecific diagnostic anent of cNOS
Our own knowledge of the metabolism of NO in the human cardiovascular system was taken as the basis and, building on that, nitrite, as a specific marker of the activity of endothelial constitutive NO synthesis, was accurately and precisely measured.
The specific stop solution mentioned in Example 2 was used, which makes it possible to prevent the rapid conversion of nitrite to nitrate in human blood without thereby resulting in any appreciable loss of nitrite during sample preparation and permitting recovery of nitrite after preparation and subsequent measurement of samples. In addition, a highly sensitive method of measurement was then developed, which by means of combined ultraviolet and electrochemical detection, integrated in a 2-channel HPLC
system, permits the simultaneous and highly sensitive quantification of nitrite and nitrate in samples of human whole blood or of that of mammals. The following results were obtained with test subjects:
In accordance with experimental studies, which have shown variable NO production in arterial and venous endothelial cells under basal conditions, a higher nitrite concentration (1310 ~ 50 nmol/L) was found in humans in arterial blood samples than in samples from venous vascular regions (1100 ~ 40 nmol/L). In contrast to this, as already mentioned above, serum values for nitrate exhibited no specific differences and on average amounted to 42 ~ 6 ~,mol/L in samples from both the arterial and venous portions of the human cardiovascular system (n - 5).
Additionally, it was shown by the model of the forearm circulatory system of man that local infusion of the endothelium-dependent dilators acetylcholine and bradykinin into the A, brachialis leads, dose-dependently, to a more than fourfold increase in flow at rest (n = 7). During this increase in flow, an increase in the serum concentration of nitrite in samples from the Vena cubitalis was documented, dose-dependently, specifically for both mediators.
Therefore, despite a more than fourfold increase in blood flow in the flow region of the forearm, a specific increase in the serum concentration of nitrite developed after infusion of the two stimulators of constitutive endothelial NO synthesis. This means that nitrite reflects, specifically and dose-dependently, increased endothelial NO
production in this flow region. In addition, a highly significant correlation was found for both substances between the increase in flow and the increase in 10 concentration of nitrite in the serum as well as the rate of release through the flow region of the forearm (see Drawings 2 and 3). Moreover, in control studies it was shown that the endothelium-independent vasodilator papaverine led to a comparable rise in blood flow by a factor of 4, without demonstrable development of an increase in the serum concentration of nitrite.
Additionally, simultaneous infusion of L-NMMA as stereospecific inhibitor of constitutive endothelial NO
synthesis (6 ~mol/min) was shown to result in a 40~
reduction in the flow response and the serum concentration of nitrite in comparison with control conditions (n - 3).
To summarize, these studies verify that, by the methodology developed, it is possible for the first time to quantify, locally and specifically, the activity of endothelial constitutive NO synthesis in the vascular system and thus to diagnose its functional state with regard to endothelial dysfunction.
2. Therapy with authentic NO solutions according to the invention in the circulatory system of mammals, especially in the human circulatory system Because of the rapid metabolism of NO in the human circulatory system, the authentic NO solutions according to the invention can be used as therapeutic agents to achieve locally very high effective concentrations of NO without triggering simultaneous deleterious systemic side effects.
The model of forearm circulation was selected and aqueous NO standards were applied locally in increasing doses to test subjects. Because of the metabolism of NO in the human blood, a continuous infusion is not suitable for this, but the bolus technique is substantially more effective. The concentrations of the stock solution selected and the kinetics of application must be chosen so that a clearly defined bolus of the aqueous NO solution, corresponding to the circular circulatory volume and the transit time from the point of application to the resistance arteries, reproducibly reaches the targeted flow region. As can be seen in Drawings 4 and 5, by means of this bolus technique NO led reproducibly to a dose-dependent increase in blood flow at the maximum as well as over the surface under the curve of the flow response, without resulting in a systemically detectable drop in blood pressure. Further, in additional toxicologic studies it was shown that at the related doses there was no reported change in the methemoglobin content in the blood of test subjects with the application of NO during the study. Additionally, with the use of the stop solution described above, it was also shown that during NO application in this regional area of flow there was an increase in serum nitrite concentration in the Vena cubitalis of 111 ~ 12%, while the serum concentration for nitrate (45 ~ 8 ~,mol/L) did not vary significantly during the intervention. The local flow response to this aqueous NO standard applied by the bolus technique correlated highly significantly with the body surface area of the individual test subjects and was independent of the level of the heart rate or of arterial systemic blood pressure.
3. Explanations of Drawings 2 to 5 Drawing 2 Relationship between variations in blood flow in the forearm (FBF) and serum concentration of nitrite (A) as well as rate of release of NO or nitrite in forearm circulation after local intra-arterial infusion of increasing doses of acetylcholine (data in Fig. 1). Linear regression analysis resulted in r = 0.997 and P = 0.003.
Drawing 3 Relationship between variations in blood flow in the forearm (FBF) and serum concentration of nitrite (A) as well as rate of release of NO or nitrite in forearm circulation after local intra-arterial infusion of increasing doses of bradykinin (data in Fig. 2). Linear regression analysis gave r = 0.985 and P = 0.001.
Drawing 4 Dose-response curve for NO-induced vasodilation in forearm circulation. The plethysmographically determined increase in blood flow in the forearm (FBF) is plotted versus the dose of NO, which was applied in bolus technique in saline standards of NO solutions (n = 6, mean ~ SEM).
r l8 Drawing 5 Dose-response curve for NO-induced vasodilation in forearm circulation. The area under the curve is plotted for variations of FBF, same test subjects as in Drawings 4/5 (n - 6, mean ~ SEM).
system, permits the simultaneous and highly sensitive quantification of nitrite and nitrate in samples of human whole blood or of that of mammals. The following results were obtained with test subjects:
In accordance with experimental studies, which have shown variable NO production in arterial and venous endothelial cells under basal conditions, a higher nitrite concentration (1310 ~ 50 nmol/L) was found in humans in arterial blood samples than in samples from venous vascular regions (1100 ~ 40 nmol/L). In contrast to this, as already mentioned above, serum values for nitrate exhibited no specific differences and on average amounted to 42 ~ 6 ~,mol/L in samples from both the arterial and venous portions of the human cardiovascular system (n - 5).
Additionally, it was shown by the model of the forearm circulatory system of man that local infusion of the endothelium-dependent dilators acetylcholine and bradykinin into the A, brachialis leads, dose-dependently, to a more than fourfold increase in flow at rest (n = 7). During this increase in flow, an increase in the serum concentration of nitrite in samples from the Vena cubitalis was documented, dose-dependently, specifically for both mediators.
Therefore, despite a more than fourfold increase in blood flow in the flow region of the forearm, a specific increase in the serum concentration of nitrite developed after infusion of the two stimulators of constitutive endothelial NO synthesis. This means that nitrite reflects, specifically and dose-dependently, increased endothelial NO
production in this flow region. In addition, a highly significant correlation was found for both substances between the increase in flow and the increase in 10 concentration of nitrite in the serum as well as the rate of release through the flow region of the forearm (see Drawings 2 and 3). Moreover, in control studies it was shown that the endothelium-independent vasodilator papaverine led to a comparable rise in blood flow by a factor of 4, without demonstrable development of an increase in the serum concentration of nitrite.
Additionally, simultaneous infusion of L-NMMA as stereospecific inhibitor of constitutive endothelial NO
synthesis (6 ~mol/min) was shown to result in a 40~
reduction in the flow response and the serum concentration of nitrite in comparison with control conditions (n - 3).
To summarize, these studies verify that, by the methodology developed, it is possible for the first time to quantify, locally and specifically, the activity of endothelial constitutive NO synthesis in the vascular system and thus to diagnose its functional state with regard to endothelial dysfunction.
2. Therapy with authentic NO solutions according to the invention in the circulatory system of mammals, especially in the human circulatory system Because of the rapid metabolism of NO in the human circulatory system, the authentic NO solutions according to the invention can be used as therapeutic agents to achieve locally very high effective concentrations of NO without triggering simultaneous deleterious systemic side effects.
The model of forearm circulation was selected and aqueous NO standards were applied locally in increasing doses to test subjects. Because of the metabolism of NO in the human blood, a continuous infusion is not suitable for this, but the bolus technique is substantially more effective. The concentrations of the stock solution selected and the kinetics of application must be chosen so that a clearly defined bolus of the aqueous NO solution, corresponding to the circular circulatory volume and the transit time from the point of application to the resistance arteries, reproducibly reaches the targeted flow region. As can be seen in Drawings 4 and 5, by means of this bolus technique NO led reproducibly to a dose-dependent increase in blood flow at the maximum as well as over the surface under the curve of the flow response, without resulting in a systemically detectable drop in blood pressure. Further, in additional toxicologic studies it was shown that at the related doses there was no reported change in the methemoglobin content in the blood of test subjects with the application of NO during the study. Additionally, with the use of the stop solution described above, it was also shown that during NO application in this regional area of flow there was an increase in serum nitrite concentration in the Vena cubitalis of 111 ~ 12%, while the serum concentration for nitrate (45 ~ 8 ~,mol/L) did not vary significantly during the intervention. The local flow response to this aqueous NO standard applied by the bolus technique correlated highly significantly with the body surface area of the individual test subjects and was independent of the level of the heart rate or of arterial systemic blood pressure.
3. Explanations of Drawings 2 to 5 Drawing 2 Relationship between variations in blood flow in the forearm (FBF) and serum concentration of nitrite (A) as well as rate of release of NO or nitrite in forearm circulation after local intra-arterial infusion of increasing doses of acetylcholine (data in Fig. 1). Linear regression analysis resulted in r = 0.997 and P = 0.003.
Drawing 3 Relationship between variations in blood flow in the forearm (FBF) and serum concentration of nitrite (A) as well as rate of release of NO or nitrite in forearm circulation after local intra-arterial infusion of increasing doses of bradykinin (data in Fig. 2). Linear regression analysis gave r = 0.985 and P = 0.001.
Drawing 4 Dose-response curve for NO-induced vasodilation in forearm circulation. The plethysmographically determined increase in blood flow in the forearm (FBF) is plotted versus the dose of NO, which was applied in bolus technique in saline standards of NO solutions (n = 6, mean ~ SEM).
r l8 Drawing 5 Dose-response curve for NO-induced vasodilation in forearm circulation. The area under the curve is plotted for variations of FBF, same test subjects as in Drawings 4/5 (n - 6, mean ~ SEM).
Claims (6)
1. Method for the determination of local NO supply in the vascular system of a mammal, comprising the steps of preventing rapid conversion of nitrite to nitrate in a blood sample by addition of a stop solution to said blood sample, and then recovering and measuring the nitrite.
2. Method according to claim 1, characterized in that the stop solution is concentrated NaOH.
3. Method according to claim 2, characterized in that immediately after addition of NaOH to the blood sample, the resulting mixture is neutralized.
4. Method according to any of claims 1 to 3, characterized in that the nitrite is recovered by the following steps:
(a) the sample is centrifuged (b) the supernatant of step (a) is decanted and ultra-filtered (c) the ultrafiltrate of step (b) is diluted with water (d) nitrite is analysed
(a) the sample is centrifuged (b) the supernatant of step (a) is decanted and ultra-filtered (c) the ultrafiltrate of step (b) is diluted with water (d) nitrite is analysed
5. Method according to claim 4, wherein the sample is centrifuged in step (a) at 10.000 g and the supernatant is ultrafiltered in step (b) at 2.000 g.
6. Method according to any of claims 1 to 5, characterized in that it is used for the diagnosis of endothelial dysfunction in mammals.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1996104361 DE19604361C2 (en) | 1996-02-07 | 1996-02-07 | Use of gas-tight primary packaging for pharmaceutical compositions |
DE19604361.1 | 1996-02-07 | ||
CA002244454A CA2244454C (en) | 1996-02-07 | 1997-02-03 | Use of nitric monoxide for preparing medication for intravascular administration |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002244454A Division CA2244454C (en) | 1996-02-07 | 1997-02-03 | Use of nitric monoxide for preparing medication for intravascular administration |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2354495A1 true CA2354495A1 (en) | 1997-08-14 |
Family
ID=25680412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002354495A Abandoned CA2354495A1 (en) | 1996-02-07 | 1997-02-03 | Method for the determination of local no supply in the vascular system of a mammal |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2354495A1 (en) |
-
1997
- 1997-02-03 CA CA002354495A patent/CA2354495A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2244454C (en) | Use of nitric monoxide for preparing medication for intravascular administration | |
Blake et al. | Hypoxic-reperfusion injury in the inflamed human joint | |
US4929602A (en) | Method of inhibiting platelet dependent arterial thrombosis | |
Blann et al. | Adverse influence of cigarette smoking on the endothelium | |
Ritchie et al. | Platelet and fibrinogen survival in coronary atherosclerosis: response to medical and surgical therapy | |
Rane et al. | Plasma protein binding of diphenylhydantoin in normal and hyperbilirubinemic infants | |
Ogilby et al. | Adequate heparinization during PTCA: assessment using activated clotting times | |
Thebault et al. | Effects of ticlopidine, a new platelet aggregation inhibitor in man | |
Cowan et al. | Two mechanisms mediate relaxation by bradykinin of pig coronary artery: NO-dependent and-independent responses | |
Jörneskog et al. | Skin capillary circulation severely impaired in toes of patients with IDDM, with and without late diabetic complications | |
Pollak | Heparin‐induced thrombocytopenia complicating extracorporeal membrane oxygenation support: Review of the literature and alternative anticoagulants | |
Naesh et al. | Platelet activation in mental stress | |
Barboriak et al. | Atherosclerosis in aortocoronary vein grafts | |
Rath et al. | Monitoring the effect of heparin by measurement of activated clotting time during and after percutaneous transluminal coronary angioplasty. | |
Bach et al. | Factors affecting the restenosis rate after percutaneous transluminal coronary angioplasty | |
Smolin et al. | Altered plasma free and protein-bound sulfur amino acid levels in patients undergoing maintenance hemodialysis | |
Rao et al. | Relationship of renal transplantation to hypertension in end-stage renal failure | |
Zimmermann et al. | The effect of bezafibrate on the fibrinolytic enzyme system and the drug interaction with racemic phenprocoumon | |
Herzlich et al. | Relationship among homocyst (e) ine, vitamin B-12 and cardiac disease in the elderly: association between vitamin B-12 deficiency and decreased left ventricular ejection fraction | |
Jokl et al. | Release of platelet plasminogen activator inhibitor 1 in whole blood is increased in patients with type II diabetes | |
CA2354495A1 (en) | Method for the determination of local no supply in the vascular system of a mammal | |
Ditter et al. | Effects of prostacyclin during cardiopulmonary bypass in men on plasma levels of β-thromboglobulin, platelet factor 4, thromboxane B2, 6-keto-prostaglandin F1α and heparin | |
HIGASHI et al. | Sodium chloride loading does not alter endothelium-dependent vasodilation of forearm vasculature in either salt-sensitive or salt-resistant patients with essential hypertension | |
Dattilo et al. | Inducible nitric oxide synthase expression in human vein grafts | |
Moelleken et al. | An adverse wound environment activates leukocytes prematurely |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |